Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 7Radiotherapy 6Bevacizumab 5Magnetic Resonance Spectroscopy 3ribociclib 2olaparib 2fluorodopa F 18 2fluciclovine F-18 2atezolizumab 2abemaciclib 2Surgical Procedures, Operative 2Specimen Handling 2Radiation 2Ketoconazole 2Everolimus 2Disulfiram 2Carvedilol 2zimberelimab 1tinostamustine 1temsirolimus 1senicapoc 1sacituzumab govitecan 1posaconazole 1pitavastatin 1perampanel 1pamiparib 1palbociclib 1niraparib 1mycophenolic adenine dinucleotide 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Glioblastoma × bemcentinib × Clear all
NCT03965494 2024-02-08

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Terminated
10 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡